Psyence BioMed raises its PsyLabs stake to 43.37% after ibogaine milestones trigger a $2.60 million backstop investment
Market Chameleon (Wed, 21-Oct 10:50 AM)
PBM Targets U.S. Pharmaceutical-Grade Ibogaine Manufacturing Through a DEA-Registered 83,000-Sq.-Ft. Texas Facility
Market Chameleon (Mon, 5-Oct 7:52 AM)
Psyence BioMed targets a Texas ibogaine trial with a US$5 million PsyLabs investment and a US$9 million share swap
Market Chameleon (Wed, 23-Sep 7:29 AM)
